These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11404464)

  • 1. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome.
    Wong AK; Alfert M; Castrillon DH; Shen Q; Holash J; Yancopoulos GD; Chin L
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7481-6. PubMed ID: 11404464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
    Kondo S; Asano M; Suzuki H
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
    Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.
    Yoshiji H; Kuriyama S; Ways DK; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Tsujinoue H; Nakatani T; Shibuya M; Fukui H
    Cancer Res; 1999 Sep; 59(17):4413-8. PubMed ID: 10485491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of vascular endothelial growth factor in the regulation of angiogenesis.
    Ferrara N
    Kidney Int; 1999 Sep; 56(3):794-814. PubMed ID: 10469350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
    J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines.
    Avramis IA; Kwock R; Avramis VI
    Anticancer Res; 2001; 21(4A):2281-6. PubMed ID: 11724283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microvascular permeability of human melanoma xenografts to macromolecules: relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression.
    Graff BA; Bjørnaes I; Rofstad EK
    Microvasc Res; 2001 Mar; 61(2):187-98. PubMed ID: 11254398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
    Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
    Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
    Fusetti L; Pruneri G; Gobbi A; Rabascio C; Carboni N; Peccatori F; Martinelli G; Bertolini F
    Cancer Res; 2000 May; 60(9):2527-34. PubMed ID: 10811135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
    Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
    Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.
    Hu L; Hofmann J; Zaloudek C; Ferrara N; Hamilton T; Jaffe RB
    Am J Pathol; 2002 Nov; 161(5):1917-24. PubMed ID: 12414537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.
    Kim ES; Serur A; Huang J; Manley CA; McCrudden KW; Frischer JS; Soffer SZ; Ring L; New T; Zabski S; Rudge JS; Holash J; Yancopoulos GD; Kandel JJ; Yamashiro DJ
    Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11399-404. PubMed ID: 12177446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanisms of hepatic sinusoidal endothelial cell regeneration: a possible communication system associated with vascular endothelial growth factor in liver cells.
    Mochida S; Ishikawa K; Toshima K; Inao M; Ikeda H; Matsui A; Shibuya M; Fujiwara K
    J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S1-5. PubMed ID: 9792028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].
    Wang F; Tian YH; Li L; Chen XF; Hu HH; Li CY; Huang Q
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Mar; 34(2):165-70. PubMed ID: 12006990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.